Central Role of Amyloid Oligomers in Alzheimer’s
Although the precise events that trigger Alzheimer’s are unknown, there is a large body of scientific evidence suggesting that amyloid peptides, particularly soluble aggregated forms, or amyloid oligomers, cause neuronal damage and cell death leading to the disease. Pathologically, Alzheimer’s disease is defined by the presence in the brain of insoluble extracellular amyloid plaques and intracellular neurofibrillary tangles that are composed primarily of tau protein.
Soluble Amyloid Oligomers = Key Driver of Alzheimer’s
Genetic Data Point to Primary Toxic Role of Amyloid in Alzheimer’s
Amyloid peptides are derived from the amyloid precursor protein, or APP, an integral membrane protein, in neurons and astrocytes in the brain. Through the enzymatic cleavage of APP, amyloid monomers are produced normally at low levels and cleared from the brain via cerebrospinal fluid. One view of Alzheimer’s disease is that APP is cleaved at an accelerated rate, producing increased amounts of soluble amyloid monomers. These monomers then aggregate to form larger soluble amyloid oligomers, which are neurotoxic and, over time, lead to loss of neuronal synapses, nerve cell dysfunction and, ultimately, nerve cell death.
The consequences of this progressive cascade include the formation of amyloid plaques, loss of brain volume, particularly in the hippocampus, and a progressive decline in cognition and the ability to function.
Recent research and clinical trials support the importance of targeting amyloid oligomers early in disease progression, including the following findings:
- Amyloid oligomer formation begins in Alzheimer’s patients years before clinical signs of the disease appear.
- Accumulation of amyloid oligomers in the brain correlates with Alzheimer’s disease progression.
- Patients with APOE4 have higher levels of amyloid oligomers compared to non-carriers, which predisposes them to increased risk and early onset of Alzheimer’s.
- Results from clinical trials of aducanumab and BAN2401, both injectable monoclonal antibodies that targets amyloid oligomers, showed reduced amyloid plaque in the brain and slowing of cognitive decline in mild Alzheimer’s patients.
We have discovered that the brain has an endogenous molecule, 3-SPA, that has potent anti-amyloid oligomer activity. 3-SPA is also the primary metabolite of tramiprosate, the active agent of ALZ-801, and, we found that its levels in the brain increased with administration of tramiprosate in clinical trials. Endogenous nature of major metabolite of tramiprosate may help explain safety, excellent brain penetration & potential efficacy of ALZ-801
ALZ-801 Pill Inhibits Formation of Amyloid Oligomers
Amyloid Oligomers Play Central Role in Alzheimer’s
Our lead product candidate, ALZ-801, is a patented, orally administered prodrug of tramiprosate that is designed to inhibit amyloid oligomer formation, a key driver of Alzheimer’s disease. We believe ALZ-801 has the potential to be differentiated from other emerging therapies targeting Alzheimer’s disease pathology due to its novel mechanism of action, oral mode of administration, potential efficacy in a genetically-targeted population. If our development program is successful and ALZ-801 is approved, we believe it has the potential to be among the first drugs to intervene in an underlying mechanism of Alzheimer’s disease.
Formation of Toxic Soluble Amyloid Oligomers Inhibited by ALZ-801
ALZ-801 Protects Native State of Beta Amyloid Protein
Multiple molecules of ALZ-801 form an enveloping cloud around Aβ42 amyloid monomer that maintains amyloid in its native shape, thereby preventing aggregation into toxic oligomers
Amyloid Conformation Enforced by ALZ-801
Influenced by surrounding cloud of excess ALZ-801 molecules, Aβ42 amyloid monomer adopts shape that blocks formation of oligomers